NXTCL Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - NextCell Pharma AB

Watchlist Manager

Watchlist

Price: 1.04 SEK -5.45% Market Closed

Market Cap: kr131.4m

N	NextCell Pharma AB STO:NXTCL	SE
	Eni SpA MIL:ENI	IT

Profitability Summary

NextCell Pharma AB's profitability score is 3/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Negative Gross Margin

-215%

Negative 3Y Average Gross Margin

-192%

Gross Margin is Increasing

-292% > -215%

Negative Operating Margin

-442%

Negative 3Y Average Operating Margin

-9 852%

Declining Operating Margin

-405% > -442%

Negative Net Margin

-437%

Negative 3Y Average Net Margin

-9 843%

Declining Net Margin

-394% > -437%

Negative Free Cash Flow Margin

-837%

Negative 3Y Average Free Cash Flow Margin

-439%

Declining Free Cash Flow Margin

-474% > -837%

Negative ROE

-85%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-3 175%

Declining ROIC

-129% > -140%

View All

Hide

Collapse

3 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.